Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 203Brain Neoplasms 94Gliosarcoma 93Glioma 88Central Nervous System Neoplasms 78Astrocytoma 66Oligodendroglioma 45Melanoma 37Medulloblastoma 18Neuroblastoma 17Neoplasm Metastasis 14Ependymoma 13Neoplasms 10Choroid Plexus Neoplasms 10Sarcoma 9Recurrence 9Optic Nerve Glioma 9Familial ependymoma 9Carcinoma, Non-Small-Cell Lung 9Ovarian Neoplasms 8Lung Neoplasms 8Spinal Cord Neoplasms 7Breast Neoplasms 7Uveal Melanoma 6Sarcoma, Ewing 6Rhabdoid Tumor 6Pinealoma 6Neuroectodermal Tumors, Primitive 6Unspecified Adult Solid Tumor, Protocol Specific 5Small Cell Lung Carcinoma 5

Interventions

gadobenic acid 2Cancer Vaccines 2Adjuvants, Immunologic 2veliparib 1tipifarnib 1interferon gamma-1b 1glutathione pegylated liposomal doxorubicin 1gadoteridol 1Trastuzumab 1Temozolomide 1Sodium Chloride 1Oncolytic Virotherapy 1Interferon-gamma 1Immunotherapy 1Dexmedetomidine 1Craniotomy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Central Nervous System Diseases × Temozolomide × Clear all
NCT00050986 2020-09-22

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

M.D. Anderson Cancer Center

Phase 1/2 Completed
55 enrolled 6 charts
CNS

Brain Neoplasms, Central Nervous System Diseases, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡